Cerity Partners
AVIR icon

Cerity Partners’s Atea Pharmaceuticals AVIR Stock Holding History

Cerity Partners’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.6K Buy
+16,471
New +$81.9K ﹤0.01% 3250

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cerity Partners's AVIR Position: Q2 2026 in Review

Cerity Partners opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2026: 16,471 shares worth $76.6K. The stake represents ﹤0.01% of the portfolio and ranks #3250 among its holdings.

125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Cerity Partners held 16,471 shares of Atea Pharmaceuticals worth $76.6K as of Q2 2026.
  • Atea Pharmaceuticals was a new Cerity Partners position in Q2 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #3250 holding.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.